NCT01982747View on ClinicalTrials.gov

A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Healthy

Interventions

DRUG

MGN-Placebo

DRUG

Placebo-MGN

Trial Locations (1)

53095

Spaulding Clinical, West Bend

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mologen AG

INDUSTRY

NCT01982747 - A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703 | Biotech Hunter | Biotech Hunter